MedTrace Logo

Efficacy of Fresh Frozen Plasma (FFP) in Treating Thrombocytopenia in Dengue Patients

NCT06642493 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-10-15

No results posted yet for this study

Summary

This clinical trial seeks to assess the effectiveness of fresh frozen plasma (FFP) in the treatment of thrombocytopenia in individuals with dengue. Dengue is a viral infection marked by thrombocytopenia, potentially resulting in significant hemorrhagic consequences. FFP is frequently utilized in the management of coagulopathies, and this study will investigate its efficacy in enhancing platelet count and mitigating bleeding risks in dengue patients with thrombocytopenia. The research will be executed as a randomized, controlled trial to evaluate outcomes in patients receiving routine care with and without FFP transfusion.

Conditions

  • Dengue Fever
  • Dengue Hemorrhagic Fever
  • Dengue Shock Syndrome

Interventions

BIOLOGICAL

Fresh frozen plasma

Intervention Type: Biological * Intervention Name: Fresh Frozen Plasma (FFP) * Detailed Description: * Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight. * Administration: The FFP will be transfused intravenously under controlled clinical conditions. * Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients. * Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion.

Sponsors & Collaborators

  • Sheikh Hasina National Institute of Burn and Plastic Surgery

    lead OTHER

Principal Investigators

  • Ashraful Hoque, DBST · Sheikh Hasina National Institute of Burn & Plastic Surgery

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06642493 on ClinicalTrials.gov